Welcome to our dedicated page for Arrowhead Pharma SEC filings (Ticker: ARWR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents give detailed insight into Arrowhead’s RNA interference (RNAi) pipeline, capital structure, collaborations, and material events affecting ARWR stock.
Arrowhead’s filings include Form 8-K current reports describing key developments such as approvals for REDEMPLO (plozasiran) in familial chylomicronemia syndrome, Breakthrough Therapy designation for investigational plozasiran in severe hypertriglyceridemia, interim clinical data for obesity candidates ARO-INHBE and ARO-ALK7, and the initiation of a Phase 1/2a study of ARO-MAPT for tauopathies including Alzheimer’s disease. Other 8-Ks outline collaboration agreements, such as the exclusive license with Novartis for ARO-SNCA, and agreements involving Visirna Therapeutics and Sanofi in Greater China.
Filings also cover Arrowhead’s capital markets transactions, including underwriting agreements for public offerings of common stock, pre-funded warrants, and 0.00% convertible senior notes due 2032. These documents describe offering terms, use of proceeds for research and development, clinical trials, commercialization activities, and related capped call transactions intended to manage potential dilution upon note conversion.
On Stock Titan, Arrowhead’s SEC filings are updated in near real time from EDGAR. Users can review annual and quarterly reports when available, as well as current reports and exhibits that detail licensing deals, clinical milestones, and regulatory actions. AI-powered summaries help explain complex sections of 10-Ks, 10-Qs, and 8-Ks in plain language, and specialized views make it easier to track insider-related disclosures and other material information relevant to ARWR investors.
Arrowhead Pharmaceuticals disclosure: Vanguard Capital Management reports beneficial ownership of 7,081,293 shares of Common Stock, representing 5.05% of the class. The filer reports sole voting power for 1,048,877 shares and sole dispositive power for 7,081,293 shares. The filing is signed on 04/29/2026.
Arrowhead Pharmaceuticals Inc ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 7,269,957 shares of common stock, representing 5.19% of the class. The filing states Vanguard has sole dispositive power over these shares and sole voting power over 123,821 shares. The holdings include securities held for Vanguard funds and managed accounts.
Arrowhead Pharmaceuticals’ Chief Financial Officer Daniel Joseph Apel sold 13,095 shares of common stock on April 22, 2026 in open-market transactions. The sales occurred at weighted average prices ranging from about $69.50 to $71.97 per share under a pre-established Rule 10b5-1 trading plan.
Following these sales, Apel directly holds 162,905 shares of Arrowhead common stock, which includes shares underlying previously reported restricted stock units that remain subject to vesting conditions. A portion of the disposition was made to satisfy tax withholding obligations related to equity compensation.
Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, sold 10,000 shares of common stock in an open-market transaction at a weighted average price of $75.00 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan. Following this sale, Hamilton directly holds 226,958 shares, including shares underlying Restricted Stock Units, some of which remain subject to vesting conditions.
Arrowhead Pharmaceuticals reports that BlackRock, Inc. beneficially owned 17,104,084 shares of Common Stock, representing 12.2% of the class as of 03/31/2026. The filing states BlackRock has sole voting power for 16,769,679 shares and sole dispositive power for 17,104,084 shares. The filing is an amendment (No. 5) to a Schedule 13G/A and is signed by a BlackRock managing director on 04/24/2026.
James Hamilton reported proposed sales of Common Stock under Rule 144. The filing lists an aggregate proposed sale of 10,000 shares and subdivided lots of 5,708, 542, 1,628, and 2,122 dated 01/04/2026. The filing also shows a prior sale of 10,000 shares on 03/05/2026 for $641,870.05.
The Vanguard GroupSchedule 13G/A reporting its holdings in Arrowhead Pharmaceuticals Inc.. The filing states amount beneficially owned: 0 shares and percent of class: 0%. It explains an internal realignment on January 12, 2026 and that certain Vanguard subsidiaries now report holdings separately, in accordance with SEC Release No. 34-39538 (January 12, 1998).
Arrowhead Pharmaceuticals reported results of its 2026 annual stockholder meeting. Stockholders elected seven directors to the board, with vote totals for each nominee ranging from about 70.4 million to 100.8 million votes in favor.
Stockholders rejected the advisory Say-on-Pay proposal, with 41,625,740 votes for and 59,963,903 votes against, signaling dissatisfaction with executive compensation. They approved the Amended and Restated 2021 Incentive Plan and ratified KPMG LLP as independent auditors. As of the January 22, 2026 record date, 140,010,690 common shares were outstanding and entitled to vote.
Arrowhead Pharmaceuticals' Chief Medical Officer sells shares under a preset plan. Chief Medical Officer James C. Hamilton executed an open-market sale of 10,000 shares of Arrowhead Pharmaceuticals common stock at a weighted average price of $64.19 per share on March 5, 2026, under a Rule 10b5-1 trading plan. After this transaction, he directly owned 236,958 shares, which include previously reported restricted stock units that remain subject to vesting conditions.